Skip to main content
3SBio Inc. logo

3SBio Inc. — Investor Relations & Filings

Ticker · 1530 ISIN · KYG8875G1029 LEI · 529900P0TQC1E9Y7FN31 HKEX Manufacturing
Open in API
Filings indexed 1,491 across all filing types
Latest filing 2022-01-21 Board/Management Inform…
Country KY Cayman Islands
Listing HKEX 1530

About 3SBio Inc.

http://www.3sbio.com

3SBio Inc. is a biopharmaceutical enterprise specializing in the integrated research, development, production, and commercialization of innovative biopharmaceutical products. The company operates as a biotechnology firm, focusing on the discovery, development, manufacture, and marketing of biologics, with a particular emphasis on mammalian cell-based biopharmaceuticals. 3SBio addresses critical medical needs by providing an extensive range of products and services to markets both domestically and internationally.

Recent filings

Filing Released Lang Actions
(1) CHANGE OF COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT&#x3b; AND (2) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND COMPOSITION OF BOARD COMMITTEES, CHANGE OF SECRETARIAL COMPA
Board/Management Information Classification · 100% confidence The document is an announcement from a company listed on the Hong Kong Stock Exchange regarding changes in its board of directors and senior management positions. It details the resignation and appointment of the company secretary, authorized representative, process agent, and an independent non-executive director, as well as changes in the composition of board committees. There is no financial data, earnings information, or report publication mentioned. The content focuses solely on management and board changes, which fits the category of Board/Management Information (MANG). The document length is over 10,000 characters, indicating it is a full announcement rather than a brief notice or report publication announcement.
2022-01-21 English
COMPLETION OF THE DISCLOSEABLE AND CONNECTED TRANSACTION INVOLVING ACQUISITION OF SALE SHARES BY MIGHTY DECADE AND OFF-MARKET SHARE BUY-BACK BY THE COMPANY
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from 3SBio Inc. regarding the completion of a discloseable and connected transaction involving the acquisition of sale shares by Mighty Decade and an off-market share buy-back by the company. It includes detailed information about the shareholding structure before and after the transaction, the fulfillment of conditions precedent, and the cancellation of buy-back shares. The content focuses on changes in share ownership and capital structure due to the share buy-back and acquisition. There are no financial statements or comprehensive financial performance data presented, so it is not an Annual Report or Interim Report. It is not a proxy solicitation, voting results, or management report. The document is a formal announcement about a capital transaction affecting shareholding and share capital. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length is over 6000 characters, indicating it is not a brief notice but a full announcement of the transaction completion.
2022-01-13 English
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF THE PRC OF THE APPLICATION FOR THE MARKET LAUNCH OF 5% MINOXIDIL FOAM
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by 3SBio Inc. regarding the acceptance by the National Medical Products Administration (NMPA) of the PRC of the company's application for the market launch of a new product, 5% Minoxidil Foam. It includes a press release detailing the clinical trial results and the regulatory acceptance of the application. The document does not contain financial statements, detailed financial analysis, or management discussion of financial results. It is not an earnings release, annual report, or interim report. It is also not a regulatory filing in the sense of compliance or certification, nor is it a report on legal proceedings, capital changes, or share transactions. The document is an announcement of a regulatory milestone related to product approval and market launch application acceptance. Given the nature of the content and the fact that it is a voluntary announcement with a press release, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-01-11 English
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 10 JANUARY 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the poll results of an Extraordinary General Meeting (EGM) held on 10 January 2022. It details the voting outcomes on resolutions related to a Share Buy-back Agreement and a Sale and Purchase Agreement, including the shareholding structure before and after the transactions. The document does not contain financial statements or detailed financial analysis but focuses on the voting results and related corporate actions. It is not a full report like an Annual Report or Interim Report, nor is it a call transcript or management discussion. It is not a proxy solicitation or remuneration report. The content fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results of shareholder resolutions at a general meeting.
2022-01-10 English
VOLUNTARY ANNOUNCEMENT - SUNSHINE GUOJIAN TO ENTER INTO A LICENSING PARTNERSHIP WITH SYNCROMUNE TO DEVELOP AND COMMERCIALIZE IMMUNO-ONCOLOGY COMBINATION THERAPY USING ANTI-PD-1 ANTIBODY 609A
Capital/Financing Update Classification · 95% confidence The document is a voluntary announcement by 3SBio Inc. regarding a licensing partnership with Syncromune to develop and commercialize an immuno-oncology therapy. It is a press release detailing the terms of the agreement, potential payments, and background information about the companies and the product involved. There are no financial statements, regulatory filings, or detailed financial performance data included. The document is not an annual or interim report, earnings release, or any form of financial supplement. It is a corporate announcement about a business development transaction, specifically a licensing agreement. This fits best under the category of Capital/Financing Update (CAP), as it relates to a significant business transaction involving potential future payments and commercialization rights, which impacts the company's capital and financing outlook. The document length (9064 characters) and content confirm it is a full announcement, not just a brief notice or report publication announcement.
2022-01-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2021
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 December 2021. It details movements in authorized and issued shares, share options, convertibles, and other share-related information. The document is submitted to the Hong Kong Exchanges and Clearing Limited and includes confirmations and remarks related to share capital and securities. It is a regulatory filing reporting share capital and securities movements rather than a financial report, earnings release, or management discussion. The document is about share capital and securities movements, which aligns with announcements related to capital changes or share issues. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length (9837 characters) and content indicate it is a full report of share capital movements, not just an announcement of a report or a certification, so it is not RPA or RNS.
2022-01-04 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.